Tenon Medical, Inc. (TNON) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary reflects a positive sentiment with strong financial performance, particularly a 32.3% revenue increase and improved gross margins. Product development is promising with new launches, and the strategic plan indicates market expansion. Despite increased operating expenses, the net loss is slightly improved. The Q&A section suggests confidence in future growth, although some responses were vague. Overall, the positive aspects outweigh the negatives, suggesting a likely positive stock price reaction.
Key Financial Performance
Revenue for Q3 2025 $1.2 million, a 32.3% increase compared to $0.9 million in the same period last year. The increase was driven by a rise in the number of surgical procedures using the Catamaran system and the addition of sales from the newly acquired SImmetry SI Joint Fusion System.
Revenue for 9 months ended September 30, 2025 $2.5 million, in line with $2.5 million in the same period in 2024. No year-over-year change was noted.
Gross Profit for Q3 2025 $0.8 million or 66% of revenue, compared to $0.4 million or 47% in the prior year quarter. The improvement in gross margin was due to higher revenue absorbing fixed overhead costs in the cost of goods sold.
Gross Profit for 9 months ended September 30, 2025 $1.3 million or 54% of revenue, compared to $1.4 million or 54% of revenue in the previous year's period. No change in gross margin percentage was noted.
Operating Expenses for Q3 2025 $4.2 million, up from $3.6 million in the prior year period. The increase was primarily due to higher sales expenses driven by higher revenue, as well as higher marketing and G&A expenses related to the SiVantage acquisition integration.
Operating Expenses for 9 months ended September 30, 2025 $11.3 million, compared to $12 million in the prior year period. The decrease was driven by lower fixed expenses, including reduced stock-based compensation.
Net Loss for Q3 2025 $3.3 million or $0.40 per share, compared to a net loss of $3.2 million or $3.63 per share in Q3 2024. The slight increase in net loss was due to higher operating expenses.
Net Loss for 9 months ended September 30, 2025 $9.7 million, compared to $10.6 million in the same period in 2024. The improvement was largely driven by reduced operating expenses and lower fixed costs.
Cash Position as of September 30, 2025 $3.4 million, compared to $6.5 million as of December 31, 2024. The decrease was due to operational expenses and investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Catamaran SE SI joint fusion system: Full commercial launch of the Catamaran SE SI joint fusion system, featuring a reduced profile for greater flexibility in treating smaller SI joint anatomy or revision procedures. It supports a minimally invasive approach and includes a proprietary instrument set.
SImmetry+ SI joint fusion system: FDA 510(k) clearance for the SImmetry+ SI joint fusion system, which introduces advancements like 3D printed titanium implants and a simplified bone graft delivery system. Alpha launch planned with select physicians.
Portfolio expansion: Acquisition of SiVantage's SImmetry and SImmetry+ sacroiliac joint fusion technologies, transforming Tenon into a multiproduct company addressing a broader spectrum of sacropelvic fixation and fusion needs.
Physician education: Hosted 26 physicians in workshops to enhance peer-to-peer engagements and adoption of new technologies.
Revenue growth: Achieved record revenue of $1.2 million in Q3 2025, a 32% increase from the same period last year, driven by Catamaran procedure volumes and SiVantage portfolio integration.
Gross margin improvement: Gross profit increased to $0.8 million (66% of revenue) in Q3 2025, up from 47% in the prior year, due to higher revenue absorbing fixed overhead costs.
SiVantage acquisition: Acquisition of SiVantage's assets, including leadership team integration, enhancing commercial execution and innovation.
Regulatory milestone: FDA clearance of SImmetry+ SI joint fusion system, expanding minimally invasive surgical approaches and strengthening competitive position.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Milestones: While the company achieved FDA 510(k) clearance for the SImmetry+ system, regulatory hurdles and delays in broader market introduction could impact the timeline for revenue generation and adoption.
Integration of SiVantage Acquisition: The integration of SiVantage's assets and team, while progressing, involves higher marketing and G&A expenses, which could strain operational efficiency and financials if not managed effectively.
Operating Expenses: Operating expenses increased to $4.2 million in Q3 2025, driven by higher sales, marketing, and integration costs. This could pressure profitability if revenue growth does not keep pace.
Cash Position and Financing: The company ended Q3 2025 with $3.4 million in cash, down from $6.5 million at the end of 2024. While a $2.85 million PIPE financing was secured, reliance on external funding could pose risks if cash burn continues at a high rate.
Market Adoption and Competition: Despite strong demand for Catamaran and SImmetry systems, competitive pressures in the sacroiliac joint fusion market could challenge market share and pricing power.
Sales and Commercial Expansion: The company is actively onboarding sales professionals and expanding its commercial footprint. However, the effectiveness of this strategy in driving revenue growth remains to be seen.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects continued revenue growth driven by increased demand for both Catamaran and SImmetry systems, supported by the recent SiVantage acquisition and expanded product portfolio.
Gross Margin Improvement: Gross margin is expected to improve as revenue increases and fixed overhead costs are further absorbed. Both SImmetry and Catamaran systems have a similar margin profile.
Product Launch and Market Expansion: The company plans an alpha launch of the SImmetry+ SI joint fusion system in the coming weeks, with broader market introduction guided by physician feedback. This is expected to strengthen the competitive position and expand market reach.
Sales Team Expansion: Tenon is actively onboarding sales professionals through a strategic hybrid structure to expand its commercial footprint and drive adoption of its product portfolio.
Regulatory and Clinical Milestones: The company aims to leverage recent FDA 510(k) clearance for SImmetry+ and ongoing clinical evidence to support broader adoption and payer coverage.
Financial Position: With $3.4 million in cash and an additional $2.85 million raised through PIPE financing, the company is positioned to execute its strategic growth initiatives.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you comment on the product revenues, specifically the base SiVantage revenues of the $1.2 million?
A:Steven Foster explained that the primary driver of revenue was record Catamaran procedures, contributing close to $1.1 million. The rest of the revenue came from early SImmetry activity, with SImmetry+ alpha launch expected to contribute to revenue growth in the coming weeks.
Q:Would you expect Catamaran to grow sequentially from Q3 '25 to Q4 '25?
A:Steven Foster confirmed that they expect Catamaran activity and surgical procedures to grow, driven by data showing its effectiveness. Additionally, the extra month of SiVantage activity and the initial phase of the SImmetry+ alpha launch are expected to contribute to growth.
Q:How should we think about the SImmetry+ alpha launch? Is it a pilot launch or a full-scale launch?
A:Steven Foster clarified that the SImmetry+ alpha launch is a pilot launch involving a small, focused group of physicians for the first 60-90 days. Feedback will be gathered to ensure the system is ready for broader use, after which the launch will expand aggressively.
Q:Is the G&A expense in Q3 reflective of what we'll see on a quarterly basis going forward?
A:Kevin Williamson stated that Q3 G&A expenses included some one-time integration costs but also reflected increased ongoing expenses. Future quarterly G&A expenses are expected to be slightly lower than Q3 but higher than previous quarters.
Q:How is the integration of SiVantage progressing? Are there additional milestones to achieve?
A:Steven Foster expressed pride in the integration progress, highlighting the team's unity and successful execution of tasks. Kevin Williamson added that the integration focused on assets, inventory, and customer base, with the SImmetry+ alpha launch being a key milestone.
Q:Can you quantify the scope of commercial sales headcount additions and explain the strategy for marketing Catamaran, SiVantage, and SImmetry+?
A:Steven Foster mentioned onboarding key commercial members and adopting a hybrid commercial structure with independent distributors and direct sales management. Salespeople will be cross-trained on all products to present a comprehensive portfolio to physicians.
Q:How are you balancing the focus on clinical data, commercial ramp-ups, and payer coverage decisions?
A:Steven Foster explained that efforts to address coding and payer coverage are handled by a separate group from the commercial organization. Both activities are prioritized equally and conducted in parallel to support growth.
Q:Review of Unclear Management Responses
A:Management did not avoid any questions directly, but some responses, such as those regarding the timeline for payer coverage decisions and the exact future G&A expenses, lacked specific details or were somewhat vague.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Catamaran SE
Catamaran system
Chief Executive
Executive Officer
PIPE financing
SI dysfunction
SI fusion
SImmetry Catamaran
SImmetry SI
SiVantage acquisition
ability
adoption
alpha
approach fusion
asset
bone
commitment
debt end
demand Catamaran
end cash
enhancement
footprint
fusion system
improvement
increase period
integration
loss share
milestone
momentum
month period
peer
platform foundation
position
score
statement
TNON Transcript
Tenon Medical, Inc. (TNON) Q1 2026 Earnings Call Transcript
Positive5-13
The company's strong Q1 performance, with a 90% revenue increase and significant gross margin improvement, is encouraging. Positive sentiments from management and analysts, along with upcoming product launches and a sustainable high gross margin, suggest a positive outlook. Despite risks like operating expenses and convertible note financing, the overall sentiment is positive, supported by optimistic guidance and strategic initiatives.
Central Asia Metals plc (CAMLF) Q4 2025 Earnings Call Transcript
Unknown3-19
The earnings call highlighted several concerns: a significant impairment charge, increased costs, and negative EPS. Although revenue grew, it was offset by rising costs and a substantial impairment. The Q&A revealed vague responses on cost management and future projects, adding uncertainty. The reinstated dividend policy is a positive, but overall, the financial health and guidance raise concerns. Given these factors, the sentiment is negative, suggesting a potential stock price decline of -2% to -8% in the short term.
Tenon Medical, Inc. (TNON) Q4 2025 Earnings Call Transcript
Positive3-19
The company demonstrated strong financial performance with a significant increase in both quarterly and annual revenue, driven by new product adoption. Gross margins improved, and net losses decreased, indicating operational efficiency. Despite competitive pressures, the strategic expansion of the product portfolio and positive reception of new launches like SImmetry+ suggest potential growth. The Q&A revealed management's optimism about revenue growth, despite vague guidance. The decrease in cash reserves is a concern but offset by strategic investments. Overall, the positive financial results and optimistic outlook suggest a positive stock price movement.
Tenon Medical, Inc. (TNON) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call summary reflects a positive sentiment with strong financial performance, particularly a 32.3% revenue increase and improved gross margins. Product development is promising with new launches, and the strategic plan indicates market expansion. Despite increased operating expenses, the net loss is slightly improved. The Q&A section suggests confidence in future growth, although some responses were vague. Overall, the positive aspects outweigh the negatives, suggesting a likely positive stock price reaction.
TNON Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
